Enhancing Membrane Repair Using Recombinant MG53/TRIM72 (rhMG53) Reduces Neurotoxicity in Alzheimer's Disease Models

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Alzheimer's Disease (AD) is a leading neurodegenerative disorder characterized by neuronal cell death.
• Amyloid beta (Aβ) peptides are key contributors to AD pathogenesis, directly impacting neuronal plasma membranes.
• Elevated Aβ levels, particularly Aβ42, cause plasma membrane repair defects in neurons, exacerbating neurodegeneration.

Purpose of the Study:

• To investigate the therapeutic potential of recombinant MG53/TRIM72 protein (rhMG53) in enhancing plasma membrane repair in Alzheimer's Disease neurons.
• To determine if rhMG53 can mitigate the neurotoxic effects of Aβ42 and patient-derived cerebrospinal fluid in neuronal models.

Main Methods:

• Utilized ex vivo and in vitro neuronal models exposed to Aβ42 or cerebrospinal fluid from AD patients.
• Administered recombinant MG53/TRIM72 protein (rhMG53) to assess its effect on plasma membrane repair capacity.
• Measured intracellular calcium levels, reactive oxygen species (ROS), and cell death as indicators of neuronal health.

Main Results:

• rhMG53 significantly enhanced plasma membrane repair in neurons treated with Aβ42 or AD patient cerebrospinal fluid.
• Treatment with rhMG53 normalized elevated intracellular calcium levels and reduced reactive oxygen species (ROS) production.
• rhMG53 administration effectively decreased neuronal cell death induced by Aβ42 and AD patient CSF.

Conclusions:

• Enhancing plasma membrane repair capacity is a promising strategy to counteract the neurotoxic effects of Aβ in Alzheimer's Disease.
• rhMG53 demonstrates potential as a therapeutic agent to protect neurons from Aβ-induced damage and cell death.
• Targeting plasma membrane repair mechanisms offers a novel therapeutic avenue for Alzheimer's Disease treatment.